Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 492

Results For "NAL"

6624 News Found

Genome Insight draws US $ 23 million in Series B Funding
Startup | May 01, 2022

Genome Insight draws US $ 23 million in Series B Funding

Funds will be allocated to accelerate rapid production and high-end curation of whole genome sequences for its clinical application


ASPIRE 2022 Congress: Recognising the 'tip of the iceberg' in the complex and chronic effects of endometriosis
Public Health | May 01, 2022

ASPIRE 2022 Congress: Recognising the 'tip of the iceberg' in the complex and chronic effects of endometriosis

It affects up to 10 per cent of women of reproductive age around the world


Philips and Prisma Health sign multi-year, long-term strategic partnership
Digitisation | April 29, 2022

Philips and Prisma Health sign multi-year, long-term strategic partnership

South Carolina’s largest health system adopts Philips software solutions for patient monitoring and enterprise imaging, helping to drive interoperability and data analytics, and deliver on Quadruple Aim


Once-weekly icodec demonstrates superior reduction in HbA1c vs degludec
Biotech | April 29, 2022

Once-weekly icodec demonstrates superior reduction in HbA1c vs degludec

In the trial, there was no statistical difference in estimated hypoglycaemia rates, and no severe hypoglycaemia events were observed for people treated with insulin icodec


Ultomiris approved in the US for adults with generalised myasthenia gravis
Drug Approval | April 29, 2022

Ultomiris approved in the US for adults with generalised myasthenia gravis

Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks


Moderna files for authorization of its Covid-19 vaccine in young children six months to six years
Biotech | April 29, 2022

Moderna files for authorization of its Covid-19 vaccine in young children six months to six years

Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children


Camzyos is the first and only USFDA-approved cardiac myosin inhibitor
Biotech | April 29, 2022

Camzyos is the first and only USFDA-approved cardiac myosin inhibitor

Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo


Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity
Biotech | April 29, 2022

Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity

Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study


Ami Organics earmarks Rs 190 cr to expand API production in Ankleshwar
News | April 29, 2022

Ami Organics earmarks Rs 190 cr to expand API production in Ankleshwar

The plant is expected to start commercial operations from Q4FY24


Diadem announces publication of peer-reviewed article on Alzheimer’s disease
Biotech | April 28, 2022

Diadem announces publication of peer-reviewed article on Alzheimer’s disease

It includes multiple studies demonstrating that post-translational modifications of conformational variants of p53 are associated with the pathogenesis of Alzheimer's Disease